×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANVS – annovis bio, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANVS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/14
11:10 am
anvs
Annovis Bio (ANVS) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $17.00 price target on the stock.
Low
Report
Annovis Bio (ANVS) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $17.00 price target on the stock.
4/10
08:30 am
anvs
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Low
Report
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
4/9
08:30 am
anvs
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
High
Report
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
4/2
07:30 am
anvs
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Medium
Report
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
3/31
12:31 pm
anvs
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication [TheStreet.com]
Low
Report
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication [TheStreet.com]
3/31
08:00 am
anvs
Annovis Publishes Historical Review of Buntanetap in The Scientist
High
Report
Annovis Publishes Historical Review of Buntanetap in The Scientist
3/19
08:10 pm
anvs
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial [Yahoo! Finance]
Low
Report
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial [Yahoo! Finance]
3/19
07:30 am
anvs
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Medium
Report
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
06:00 am
anvs
Form 8-K Annovis Bio, Inc. For: Apr 09
Medium
Report
Form 8-K Annovis Bio, Inc. For: Apr 09
4/3
05:06 pm
anvs
Form 4 Annovis Bio, Inc. For: Apr 02 Filed by: Hoffman Michael B
Medium
Report
Form 4 Annovis Bio, Inc. For: Apr 02 Filed by: Hoffman Michael B
4/2
04:39 pm
anvs
Form 144 Annovis Bio, Inc. Filed by: White Mark K.
Medium
Report
Form 144 Annovis Bio, Inc. Filed by: White Mark K.
3/25
05:19 pm
anvs
Form 8-K Annovis Bio, Inc. For: Mar 23
Medium
Report
Form 8-K Annovis Bio, Inc. For: Mar 23
3/16
05:06 pm
anvs
Form 8-K Annovis Bio, Inc. For: Mar 16
Low
Report
Form 8-K Annovis Bio, Inc. For: Mar 16
3/13
05:16 pm
anvs
Form 10-K Annovis Bio, Inc. For: Dec 31
High
Report
Form 10-K Annovis Bio, Inc. For: Dec 31
2/12
09:01 am
anvs
Form 8-K Annovis Bio, Inc. For: Feb 12
Low
Report
Form 8-K Annovis Bio, Inc. For: Feb 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/28
Annovis Bio Announces Pricing of Initial Public Offering
44.6%
4/3 Form 8-K Annovis Bio, Inc. For: Apr 03 15.0%
2/13 Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease 10.5%
4/13 Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14 5.8%
4/30 Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients 5.3%
1/31 Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.4%
3/25 Form 10-K Annovis Bio, Inc. For: Dec 31 2.3%
4/20 Form SC 13D Annovis Bio, Inc. Filed by: Maccecchini Maria-Luisa 1.3%
4/23 Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies 0.3%
4/3 Form 8-K Annovis Bio, Inc. For: Apr 03 15.0%
2/13 Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease 10.5%
4/13 Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14 5.8%
4/30 Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients 5.3%
1/31 Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.4%
3/25 Form 10-K Annovis Bio, Inc. For: Dec 31 2.3%
4/20 Form SC 13D Annovis Bio, Inc. Filed by: Maccecchini Maria-Luisa 1.3%
4/23 Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies 0.3%
TOP News Decliners
1/30
Form 424B4 Annovis Bio, Inc.
-26.7%
2/14 Form S-8 Annovis Bio, Inc. -10.3%
2/6 Form 8-K Annovis Bio, Inc. For: Jan 30 -9.3%
3/19 Annovis Bio to Present at the Online Spring Investor Summit on March 25 -7.0%
5/1 Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report -3.9%
2/20 Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases -3.2%
2/5 Form 4 Annovis Bio, Inc. For: Jan 31 Filed by: Bruck Claudine -2.9%
4/15 Annovis up 23% after webinar on neurodegeneration candidates [Seeking Alpha] -2.6%
2/27 Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies -0.4%
2/14 Form S-8 Annovis Bio, Inc. -10.3%
2/6 Form 8-K Annovis Bio, Inc. For: Jan 30 -9.3%
3/19 Annovis Bio to Present at the Online Spring Investor Summit on March 25 -7.0%
5/1 Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report -3.9%
2/20 Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases -3.2%
2/5 Form 4 Annovis Bio, Inc. For: Jan 31 Filed by: Bruck Claudine -2.9%
4/15 Annovis up 23% after webinar on neurodegeneration candidates [Seeking Alpha] -2.6%
2/27 Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies -0.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: